Tag: CB Therapeutics - Psychedelic Alpha

Our 2022 Year in Review is now live.

Read more about the article CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research

CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research

Post published:May 19, 2022
Post category:Press Release

Read more about the article Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities

Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities

Post published:December 20, 2021
Post category:Press Release

CB Therapeutics Expands Biomanufacturing IP Portfolio

Post published:August 24, 2021
Post category:Press Release

CB Therapeutics Closes on Oversubscribed Series A

Post published:May 10, 2021
Post category:Press Release

CB Therapeutics Achieves Major Breakthrough in the Biosynthesis of Psilocybin, Psilocin and Related Tryptamine-based Compounds

Post published:December 4, 2019
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Insights and interviews delivered to your inbox. No spam, just valuable information.

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for psychedelic research

Two esteemed doctors join CB Therapeutics in its exploration of innovative approaches to the production of novel psychedelics and cannabinoids so researchers can address the unmet needs of patient communities

CB Therapeutics Expands Biomanufacturing IP Portfolio

CB Therapeutics Closes on Oversubscribed Series A

CB Therapeutics Achieves Major Breakthrough in the Biosynthesis of Psilocybin, Psilocin and Related Tryptamine-based Compounds

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.